Safe combination therapy in patients with hypertension and metabolic syndrome: the STAR-LET study
https://doi.org/10.18705/1607-419X-2008-14-4-391-396
Abstract
Unfavorable metabolic effects and possible diabetes type 2 development in patients with arterial hypertension and metabolic syndrome taking diuretics over a long period of time are under discussion. According to the results of the STAR study fixed-dose combination drug «TARKA» trandolapril + verapamil CP (T/V) had a definite advantage over combination therapy with angiotensin II receptor antagonists (ARA) lozartan and hydrochlorthyazide (L/H) considering glycemia control and the risk of diabetes development. A sample of patients included in STAR study took part in a 6-month-long project STAR-LET. Those who were prescribed for the T/V therapy initially continued this treatment, and the ones taking L/H began T/V therapy. The results of oral glucose tolerance test (the 2 hour glucose level) are the following: the glucose level did not change significantly in the group of patients taking T/V from the beginning of the STAR study as compared to the initial level (7,7 ± 2,4 vs 8,1 ± 3,3, p > 0,05), and it improved in subjects taking T/V after L/H therapy (8,5 ± 3,0 vs 7,2 ± 2,3, p < 0,001). Thus, STAR-LET study showed benefits of «TARKA» in subjects with metabolic syndrome and arterial hypertension - its metabolic neutrality as well as its ability to improve impaired glucose tolerance resulting from thiazide diuretic therapy.
About the Authors
N. Sh. Zagidullin
Bashkiria State Medical University of Health Care of Roszdrav , Ufa
Russian Federation
Russian Federation
Sh. Z. Zagidullin
Bashkiria State Medical University of Health Care of Roszdrav , Ufa
Russian Federation
Russian Federation
References
1. Беленков Ю.Н. и рабочая группа следователей ЭПИГАФ-2. Эналаприл плюс Индапамид в лечение АГ: оценка эффективности и безопасности Рациональной Фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2. //Сердце. 2005. Том 4, №5. С.277-286.
2.
3. Кобалава Ж.Д., Котовская В. Значение фиксированной комбинации верапамил СР/трандолаприл в лечение пациентов с метаболическим синдромом: результаты исследования STAR // Кардиология. 2007. Т.47, №9. С.65-70.
4.
5. Лопатин Ю.М. Фиксированные низкодозовые комбинации антигипертензивных средств с позиции препаратов первого выбора для лечения артериальной гипертонии //Сердце. 2006. Том 4, №3. С.113-155.
6.
7. Фомин И.В. Артериальная гипертония в Российской Федерации - последние десять лет. Что дальше? // Сердце. 2007. 6, №3, С.120-123.
8.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trail (ALLHAT). JAMA 2002;288:2981-2997.
10.
11. Bakris G., Molitch M., Hewkin M. et al. Difference in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;12:2592-2597.
12.
13. Bakris G., Molitch M., Zhou Q. et al. Reversal of Diuretic-Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. J Cardiometab Syndr 2008;3:18-25.
14.
15. Bonora E., Kiechl S., Willeit J., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 Oct;47(10):1643-9.
16.
17. Chobanian A.V. Antihypetensive therapy in evalution. N Engl J Med1986;314:1701-1702.
18.
19. Chobanian A.V., Bakris G.J., Black H.R. et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003:42;1206-1252.
20.
21. Christensen D.B., Williams B., Goldberg H.I. et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1999;35(11):1164-70.
22.
23. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part2: short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.
24.
25. Cooper-Dehoff R., Cohen J.D., Bakris G.L. et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (finding from the International VErapamil SR-Trandalapril Study [INVEST]). Am J Cardiol 2006;98:890-894.
26.
27. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
28.
29. Dahlof B., Sever P.S., Poulter N.R. For the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding preindopril as required versus atenolol adding bendroflumethiazide as required, in the Angio-Scandinavian Cardiac Outcomes Trail-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
30.
31. Dickerson J.E., Hingorani A.D., Ashby M.J. et al. Optimization of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353(9169):2008-13.
32.
33. Elliot W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 20070;369(9557):201-7.
34.
35. European Society of Hypertention-European Society of Cardiology guidelines for the management of arterial hypertention. J Hypertens 2003:21;1011-1053.
36.
37. Frishman W.H., Ram CV.S., McMahon F.G. et al. Comparison of amlodipine and benazepril monotherapy to amlodipinde plus nenazepril in patients with systemic hypetension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Groups. J Clin Pharmacol 1995;35:1060-1066.
38.
39. Kjekdsen SE, Jamerson K.A., Bakris G.L. et.al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension:the ACCOMPLISH study. Blood Press 2008;17(1):7-17.
40.
41. Messerli F., Frishman W.H., Elliott W.J., Bacher P.H., Pepine C.J. Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. Blood Press Suppl 2007;1:6-9.
42.
43. Taylor E., Hu F., Curhan G.C. Antihypetensive medications and the risk of incident type 2 diabetes. Cardiovascular and Metabolic Risk. Diabetes Care 2006;29(5):1065-70.
44.
45. The National Cholesterol Education Program Expert Panel (NCEP) on Detection, Evaluation, and Treatment of High Blood Chplesterol in Adults (Adult Treatment Panel III). JAMA 2001;286:2486-2497.
46.
47. Verdecchia P., Reboldi G., Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-969.
48.
49. Weder B.A. The avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: a comparison of first line combination therapies. Expert Opin Pharmacother 2005;6(2):275-281.
50.
Review
For citations:
Zagidullin N.Sh., Zagidullin Sh.Z. Safe combination therapy in patients with hypertension and metabolic syndrome: the STAR-LET study. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(4):391-396. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-4-391-396
Views:
953
Email this article 